A Phase 3 interventional study of Myocet in Breast Cancer, sponsored by Sopherion Therapeutics. Status unknown at 105 sites in 11 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-03-31.
Sponsored by Sopherion Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 197 studies testing doxorubicin in Breast Neoplasms — 9 open to participants now, 18 under way, 5 of them phase 3. Doxorubicin · Breast Neoplasms.
Among the 197 studies testing doxorubicin in Breast Neoplasms, this one is the 20th largest by enrollment of the 189 interventional ones that give a count, is one of 19 that started in 2006, is one of 28 in phase 3, and was the 64th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →9 of the 197 studies testing doxorubicin in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18–70
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–70 · Women only
SCRI Development Innovations, LLC · Sites in United States
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–70 · Women only
By country, each count listing its studies:
Doxorubicin: first FDA approval 1974 (DOXORUBICIN HYDROCHLORIDE), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
197 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 126 · Phase 3 30 · Phase 4 9
First in 1993; this study’s year is marked. 19 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 363 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 56 across the 189 interventional studies. Of the 142 that completed or were terminated, 69 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 197 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Sopherion Therapeutics as lead sponsor.
Sopherion Therapeutics has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies testing doxorubicin in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05645380University of Kansas Medical CenterNeoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | 2026-12 |
| NCT02897700Shanghai Jiao Tong University School of MedicineA Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast | 2026-12 |
| NCT03971409Laura Huppert, MD, BAAvelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | 2027-01-31 |
| NCT05748834SCRI Development Innovations, LLCStudy of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 197 studies testing doxorubicin in Breast Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to examine the safety and effectiveness of the drug combination of Myocet, paclitaxel and trastuzumab compared to paclitaxel and trastuzumab without Myocet, as first line treatment for patients with metastatic HER2+ breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study also gives Trastuzumab. No intervention listed here names it: that was found by reading the record.
Progression-Free Survival
Overall Survival
Safety
Showing the first 100 of 105 sites across 11 countries. Choose a country and city above to see the rest.
This study is status unknown, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Doxorubicin